B-ALL Clinical Trial - Evaluate the Safety, Efficacy & Pharmacokinetics of

Updated 06/21/2024

Status Recruiting

Clinical Trial Summary

This is an open label, phase I study to assess the safety, efficacy and pharmacokinetics of ThisCART19A in patients with MRD+ B-ALL

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

B-ALL

Clinical Trial Details

NCT number	NCT05350852
Study type	Interventional
Source	Zhejiang University
Contact	Mingming z Zhang, Doctor
Phone	13656674208
Email	mingmingzhang@zju.edu.cn
Status	Recruiting
Phase	Phase 1
Start date	March 18, 2022
Completion date	April 30, 2024

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT04088890` - Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies	Phase 1
	Recruiting	`NCT04546906` - Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia	N/A
	Recruiting	`NCT04546893` - Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia	N/A
	Active, not recruiting	`NCT01209286` - Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)	Phase 2
	Withdrawn	`NCT05571540` - Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL	Phase 1/Phase 2
	Completed	`NCT01290120` - Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma	Phase 2
	Recruiting	`NCT04781634` - a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL	Phase 1/Phase 2
	Recruiting	`NCT03448393` - CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies	Phase 1
	Recruiting	`NCT05350787` - Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL	Phase 1
	Recruiting	`NCT05621291` - A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...	N/A
	Active, not recruiting	`NCT04318678` - CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)	Phase 1
	Active, not recruiting	`NCT04499573` - Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL	Phase 1/Phase 2
	Recruiting	`NCT04512716` - Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma	Early Phase 1
	Active, not recruiting	`NCT03751709` - Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL	Phase 1
	Recruiting	`NCT05639179` - Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL	Phase 1/Phase 2
	Recruiting	`NCT04792593` - Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia	N/A
	Recruiting	`NCT05442515` - CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies	Phase 1/Phase 2
	Active, not recruiting	`NCT02328014` - Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies	Phase 1/Phase 2
	Active, not recruiting	`NCT02315612` - Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies	Phase 1